SEARCH

SEARCH BY CITATION

References

  • 1
    Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 17: 16761687.
  • 2
    Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 2335.
  • 3
    Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 1: 4356.
  • 4
    McKeage, K. Eculizumab: A review of its use in paroxysmal nocturnal haemoglobinuria. Drugs 2011; 17: 23272345.
  • 5
    Al-Akash SI, Almond PS, VH Savell, Jr., et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 4: 613619.
  • 6
    Chatelet V, Fremeaux-Bacchi V, Lobbedez T, et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 11: 26442645.
  • 7
    Davin JC, Gracchi V, Bouts A, et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH Mutation. Am J Kidney Dis 2010; 55: 708711.
  • 8
    Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 5: 544546.
  • 9
    Larrea CF, Cofan F, Oppenheimer F, et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 7: 903904.
  • 10
    Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 8: 13121316.
  • 11
    Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 5: 542544.
  • 12
    Dorresteijn EM, van de Kar NC, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 2012; 7: 11931195.
  • 13
    Duran CE, Blasco M, Maduell F, et al. Rescue therapy with eculizumab in a transient recipient with atypical haematologic-uraemic syndrome. Clin Kidney J 2012; 1: 2830.
  • 14
    Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 2012; 1: 3436.
  • 15
    Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 14881494.
  • 16
    Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 8: 13251329.
  • 17
    Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 18: 17461748.
  • 18
    Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12: 19381944.
  • 19
    Chandran S, Baxter-Lowe L, Olson JL, et al. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation—a case report. Transplant Proc 2011; 5: 20972101.
  • 20
    Wilson CH, Brown AL, White SA, et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011; 8: e42e43.
  • 21
    Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 16941701.
  • 22
    Greenbaum LA, Babu S, Furman RR, et al. Continued improvement in renal function with sustained eculizumab in patients with atypical HUS resistant to plasma exchange/infusion. In: 44th Annual Meeting of the American Society of Nephrology ; 2011, J.A.S.N.S. 197A, Editor: Philadelphia, PA , USA .
  • 23
    Greenbaum LA, Babu S, Furman RR, et al. Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome resistant to plasma exchange/infusion: Results of an extension study. In: 53th Annual Meeting of the American Society of Hematology ; 2011: San Diego , CA , USA .
  • 24
    Legendre C, Babu S, RR Furman, et al. Safety and efficacy of eculizumab in aHUS resistant to plasm therapy: Interim analysis from a phase II trial. In 43rd Annual Meeting of the American Society of Nephrology ; 2010, JASN (suppl): 93A, Editor: Denver, CO , USA .
  • 25
    Licht C, Muus P, Legendre C, et al. Eculizumab is an effective long-term treatment in patients with atypical haemolytic uremic syndrome previously receiving chronic plasma exchange/infusion: Extension study results. In: 53th Annual Meeting of the American Society of Hematology ; 2011: San Diego , CA , USA .
  • 26
    Licht C, Muus P, Legendre C, et al. Phase II study of eculizumab in patients with atypical HUS receiving chronic plasma exchange/infusion. In: 44th Annual Meeting of the American Society of Nephrology ; 2011 J Am Soc Nephrol 2011; 22(suppl): 197A: Philadelphia, PA , USA .
  • 27
    Muus P, Legendre C, Douglas K, et al. Safety and efficacy in aHUS patients on chronic plasma therapy: Interim analysis of a phase II trial. In: 43rd Annual Meeting of the American Society of Nephrology ; 2010 JASN (suppl): 402A, Editor: Denver, CO , USA .
  • 28
    Chatelet V, Lobbedez T, Fremeaux-Bacchi V, et al. Eculizumab: Safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Case report. Transplant Proc 2010; 10: 43534355.
  • 29
    Ardissino G, Testa S, Paglialonga F, et al. Remission of plasma-resistant atypical hemolytic uremic syndrome relapse on kidney graft with eculizumab. In: 2nd International Conference on HUS-MPGN-PNH ; 2010: Innsbruck, Austria . p. 17.
  • 30
    Heyne N, Terminal complement blockade by eculizumab effectively reverses recurrent atypical hemolytic uremic syndrome after kidney transplantation. In: 44th Annual Meeting of the American Society of Nephrology ; 2011: Philadelphia, PA , USA .
  • 31
    Legault D, Boelkins M, Succesful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. In: 51st Annual meeting of the American Society of Hematology ; 2009: Grand Rapids , MI . p. 2421.
  • 32
    Koskinen AR, Tukiainen E, Arola J, et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. Am J Transplant 2011; 9: 18851895.
  • 33
    Davin JC, Buter N, Groothoff J, et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009; 9: 17571760.
  • 34
    Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 24052413.
  • 35
    Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 18: 17441475.
  • 36
    Kose O, Zimmerhackl LB, Jungraithmayr T, et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thrombosis Hemostasis 2010; 6: 669672.
  • 37
    English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 1: 135141.
  • 38
    Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 11: 25612570.
  • 39
    Tschumi S, Gugger M, Bucher BS, et al. Eculizumab in atypical hemolytic uremic syndrome: Long-term clinical course and histological findings. Pediatr Nephrol 2011; 11: 20852088.
  • 40
    Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 8: 180418011.
  • 41
    Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012; 12: 25462553.
  • 42
    Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 12291237.
  • 43
    Summary of Product Characteristics, S., European Commission Available at: http://www.medicines.org.uk/emc/medicine/19966/SPC/soliris./ Accessed November 29, 2011.
  • 44
  • 45
    Brodsky RA, de Castro CIII, Schrezenmeier H, et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH). In: 52nd Annual Meeting of the American Society of Hematology : Orlando, FL , USA .
  • 46
    Highlights of Prescribing Information, S., U.S. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf. Accessed Septe mber 23, 2011.
  • 47
    Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 4: 687696.
  • 48
    Saland JM, Ruggenenti P, and Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009; 5: 940949.
  • 49
    Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 1: 3747.